Preliminary PET Study of 18F-FC119S in Normal and Alzheimer's Disease Models

Se Jong Oh, Min Hwan Kim, Sang Jin Han, Kyung Jun Kang, In Ok Ko, Youngsoo Kim, Ji Ae Park, Jae Yong Choi, Kyo Chul Lee, Dae Yoon Chi, Yong Jin Lee, Kyeong Min Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To evaluate the efficacy of 18F-FC119S as a positron emission tomography (PET) radiopharmaceutical for the imaging of Alzheimer's disease (AD), we studied the drug absorption characteristics and distribution of 18F-FC119S in normal mice. In addition, we evaluated the specificity of 18F-FC119S for β-amyloid (Aβ) in the AD group of an APP/PS1 mouse model and compared it with that in the wild-type (WT) group. The behavior of 18F-FC119S in the normal mice was characteristic of rapid brain uptake and washout patterns. In most organs, including the brain, 18F-FC119S reached its maximum concentration within 1 min and was excreted via the intestine. Brain PET imaging of 18F-FC119S showed highly specific binding of the molecule to Aβ in the cortex and hippocampus. The brain uptake and binding values for the AD group were higher than those for the WT group. These results indicated that 18F-FC119S would be a candidate PET imaging agent for targeting Aβ plaque.

Original languageEnglish
Pages (from-to)3114-3120
Number of pages7
JournalMolecular Pharmaceutics
Volume14
Issue number9
DOIs
Publication statusPublished - 2017 Sep 5

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Preliminary PET Study of <sup>18</sup>F-FC119S in Normal and Alzheimer's Disease Models'. Together they form a unique fingerprint.

  • Cite this

    Oh, S. J., Kim, M. H., Han, S. J., Kang, K. J., Ko, I. O., Kim, Y., Park, J. A., Choi, J. Y., Lee, K. C., Chi, D. Y., Lee, Y. J., & Kim, K. M. (2017). Preliminary PET Study of 18F-FC119S in Normal and Alzheimer's Disease Models. Molecular Pharmaceutics, 14(9), 3114-3120. https://doi.org/10.1021/acs.molpharmaceut.7b00351